Annie Showers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Annie Showers has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Ada Yu
Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
1 shared publication - Amene Majidipur
Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
1 shared publication - Asma Boukhalfa
Molecular Cardiology Research Institute, Tufts Medical Center, Boston, MA 02111, USA
1 shared publication - Cheryl A. London
Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 01536, USA
1 shared publication - David E. Sosnovik
Cardiovascular Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, USA
1 shared publication - Dawn M. Meola
Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA 01536, USA
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 845
Carvedilol Exerts Cardioprotective Effects Against Doxorubicin Toxicity via Autophagy Modulation and Energetics Restoration
Background/Objectives: Carvedilol is an adrenergic blocker FDA-approved to improve outcomes in heart failure with reduced ejection fraction. Clinical trials examining whether carvedilol may be cardioprotective in the setting of cancer therapy-induced heart failure have generated mixed results that may depend on the cancer regimen, tumor, or comorbidities. Methods: To investigate the therapeutic potential of carvedilol to mitigate doxorubicin cardiotoxicity in cardiomyocytes, myocardial tissue, and in vivo, independent of confounding factors in clinical studies, we utilized disease-free cardiac slices and cardiomyocytes from mice, dogs, and human in vitro, and in wildtype mice injected with doxorubicin in vivo. We further evaluated the impact of carvedilol in dogs with cancer receiving doxorubicin. Results: In primary canine and murine cardiac slices, carvedilol treatment restored autophagy and prevented apoptosis from doxorubicin. Carvedilol restored mitochondrial energetics in human, canine, and murine models. In wildtype mice challenged with doxorubicin, carvedilol prevented declines in cardiac function and alterations in cardiac structure. In pet dogs with cancer and undergoing doxorubicin treatment, carvedilol was beneficial in preserving cardiac function and structure. Conclusions: Carvedilol activates cardioprotective autophagy, arrests doxorubicin-induced cell death, and improves energetics and cardiac structure and function across species.
- 28 May 2026
- Published by MDPI AG in Pharmaceuticals
- Vol. 19 (6) , 845
Open AccessCarvedilol Exerts Cardioprotective Effects Against Doxorubicin Toxicity via Autophagy Modulation and Energetics Restoration
Background/Objectives: Carvedilol is an adrenergic blocker FDA-approved to improve outcomes in heart failure with reduced ejection fraction. Clinical trials examining whether carvedilol may be cardioprotective in the setting of cancer therapy-induced heart failure have generated mixed results that may depend on the cancer regimen, tumor, or comorbidities. Methods: To investigate the therapeutic potential of carvedilol to mitigate doxorubicin cardiotoxicity in cardiomyocytes, myocardial tissue, and in vivo, independent of confounding factors in clinical studies, we utilized disease-free cardiac slices and cardiomyocytes from mice, dogs, and human in vitro, and in wildtype mice injected with doxorubicin in vivo. We further evaluated the impact of carvedilol in dogs with cancer receiving doxorubicin. Results: In primary canine and murine cardiac slices, carvedilol treatment restored autophagy and prevented apoptosis from doxorubicin. Carvedilol restored mitochondrial energetics in human, canine, and murine models. In wildtype mice challenged with doxorubicin, carvedilol prevented declines in cardiac function and alterations in cardiac structure. In pet dogs with cancer and undergoing doxorubicin treatment, carvedilol was beneficial in preserving cardiac function and structure. Conclusions: Carvedilol activates cardioprotective autophagy, arrests doxorubicin-induced cell death, and improves energetics and cardiac structure and function across species.